geal echocardiography (TOE) revealed severe calcific AS and LVOT mass measuring 2.1*1.5 cm. The patient was turned down for surgery. It was decided that transcatheter aortic valve implantation (TAVI) be performed because the valve compresses the mass against the proximal part of the interventricular septum. The mass peduncle was 1.4 cm, and it was 4 mm away from the annulus. This meant the valve was needed to be deployed 18 mm below the annulus to cover the mass completely. Gentle manipulation and direct valve deployment without preballoon dilation to decrease the possibility of fragment embolization were necessary. Self-expandable core valve deployed as low as possible, after initial deployment, the distance of LVOT covered by the valve measured by TOE 1.66 cm, the whole mass was covered, then the valve was fully deployed. The patient was extubated in the catheterization room; there was no clinical evidence of embolization. The patient was discharged home after 2 days. A follow-up TTE after 6 months showed a well-functioning valve and the LVOT mass then disappeared. 
. Discussion
Pedunculated LVOT mass should be resected surgically. In high-risk surgical patients, direct TAVI to compress the mass is feasible in experienced canters. The safety issues need more research and more cases to judge. Transoesophageal echocardiography during the procedure is mandatory to guide the valve position.
Keywords

LVOT • Mass • TAVI • Case report
Learning points
• How to use the transoesophageal echocardiography in guiding transcatheter aortic valve implantation (TAVI) in presence of left ventricular outflow tract (LVOT) mass? The distance from the AV annulus to the end of the mass should be covered with the valve.
• Pedunculated LVOT mass should be resected surgically. In high-risk surgical patients, direct TAVI to compress the mass is feasible and safe in experienced centres. Transoesophageal echocardiography during the procedure is mandatory to guide the valve position.
• The mass should be within 18 mm from the AV annulus to be covered by the valve. Only self-expandable valves can be used in this scenario to allow low implantation to include the mass.
Introduction
Mobile masses in the left ventricular outflow tract (LVOT) with embolic potential should be surgically resected. Pagel et al. 1 reported a case of a highly mobile papillary fibroelastoma in the LVOT proximal to a calcified stenotic aortic valve. In contrast to this case, the mass was surgically removed during surgical aortic valve replacement. Isolated LVOT myxoma is rarer than an LVOT papillary fibroelastoma. Coats et al. 2 reported surgical resection of papillary fibroelastoma arising from the LVOT; the lesion was small and resembled a 'sea anemone' with a gelatinous membrane and multiple papillary projections. Benign cardiac myxomas constitute 88% of cardiac tumour cases; left ventricular myxomas account for 2.5% of cases. 3 Complications of LVOT mass are mainly caused by embolization, obstruction to LVOT, arrhythmias, and conduction disturbances. 4 In this case report, we discussed other techniques for the removal of mass that caused LVOT obstruction in patients at high risk of surgery. Here, we successfully treat severe aortic stenosis (AS) and the LVOT mass with transcatheter aortic valve implantation (TAVI). Leaving the pedunculated LVOT mass for conservative management had an inferior outcome compared with those who underwent surgery. . The continuity equation is not accurate in the presence of two successive stenotic lesions. This PG was due to valvular AS because the LVOT had enough space beyond the mass. Also, the envelope of aortic valve Inflow was of fixed obstruction and not the late peaking dagger shape of dynamic obstruction. Because the thrombus possibility was very low, anticoagulation could not be started. The patient was turned down for surgery due to his age and associated pulmonary problems. We think to do alcoholic septal ablation aiming to reduce the size of the mass by reducing its blood supply then to do TAVI. However, it was decided to perform TAVI because the valve compresses the mass against the proximal part of the interventricular septum. We decided not to take a biopsy from the mass to avoid manipulation with a higher possibility of embolization. The mass peduncle was 1.4 cm and 4 mm away from the annulus. This meant that the valve needed to be deployed 18 mm below the annulus to cover the mass completely. Also, gentle manipulation and direct valve deployment without preballoon dilation to decrease the possibility of fragment embolization. Self-expandable 26 core valve expanded 60% deep in left ventricle, and then the valve pulled up to its original position to include the whole mass. The valve was intentionally implanted 16 mm below the annulus to cover the mass (Figure 2) . We planned for second valve in valve in case of significant leak due to low implantation. Fortunately, the valve implanted and the mass covered with no leak. This technique cannot be done with balloon-expandable valves. The patient was extubated in the catheterization room, and there was no clinical evidence of embolization. The patient was discharged home after 2 days. A follow-up TTE after 6 months showed a wellfunctioning valve, and the LVOT mass disappeared (Figure 3 ).
Discussion
The differential diagnosis of this mass either a thrombus, vegetation, or a tumour. Thrombophilia screen, autoimmune diseases, and hypereosinophilia screen were normal, making the possibility of thrombus very low, especially with normal left ventricular function. There was no fever or any clinical symptoms suggesting endocarditis and negative blood cultures, so the possibility of vegetation was unlikely. Tumour in the LVOT may be fibroelastoma, myxoma, or a rare malignant tumour. The most important feature of a cardiac myxoma is its narrow stalk; also, a myxoma is homogeneous and may have a hyperlucent central area, indicating haemorrhage and necrosis. Patients with an LVOT myxoma are usually asymptomatic. However, most clinical symptoms related to left ventricular myxoma are caused by embolization and LVOT obstruction. 7 The high pressure of the left ventricle during systole can increase the risk of systemic embolization, so a cardiac mass originating in LVOT should be removed immediately. 8 Finkelstein et al. 9 reported a case where severe valvular AS and subvalvular discrete subaortic stenosis were treated with TAVI. Unlike this case, there was no mobile mass and no fear of embolization. In this case report, the authors raise the possibility of treating LVOT masses with TAVI even in the absence of AS provided there was enough calcification to withhold the valve. This is out-of-label use and needs more research. The mass should be within 18 mm from the AV annulus to be covered by the valve. Self-expandable valves are better used in these cases to allow low implantation to include the mass. More research is required to support this approach.
To the best of our knowledge, this is the first reported case of treating LVOT mass with TAVI. We want to emphasize that the main indication of TAVI in this case is the severe symptomatic AS in a high-risk surgical patient. The presence of the LVOT mass was a coincident finding and not the primary purpose for TAVI.
Conclusion
Pedunculated LVOT mass should be resected surgically. In high-risk surgical patients, direct TAVI to compress the mass is feasible in experienced canters. The safety issues need more research and more cases to judge. Transoesophageal echocardiography during the procedure is mandatory to guide the valve position. 
